Health status in patients treated with cardiac resynchronization therapy: modulating effects of personality

Angélique A Schiffer1, Johan Denollet, Susanne S Pedersen

  • 1CoRPS-Center of Research on Psychology in Somatic diseases, Tilburg University, The Netherlands. Angelique.schiffer@uvt.nl

Insights

Cardiac resynchronization therapy (CRT) improves chronic heart failure outcomes. However, negative affectivity personality traits consistently worsen patient health status and symptoms despite CRT.

Area of Science:

  • Cardiology
  • Psychology

Background:

  • Cardiac resynchronization therapy (CRT) is a key treatment for chronic heart failure (CHF).
  • A subset of patients experience persistent symptoms and disability post-CRT.
  • Understanding factors influencing CRT outcomes is crucial.

Purpose of the Study:

  • To assess improvements in patient-centered outcomes and functional capacity after CRT in CHF patients.
  • To investigate the impact of personality traits, specifically negative affectivity, on these outcomes over two months.

Main Methods:

  • 31 CHF patients undergoing CRT were analyzed.
  • Patients completed personality, health status, and disability questionnaires pre-CRT and two months post-CRT.
  • Functional capacity was measured using the six-minute walking test.

Main Results:

  • Significant improvements were observed in health status, cardiac symptoms, disability, and functional capacity post-CRT.
  • Patients with high negative affectivity reported worse health status, more symptoms, and greater disability compared to those with low negative affectivity.
  • Negative affectivity demonstrated a moderate to large effect size on patient-centered outcomes.

Conclusions:

  • CRT improves patient-centered outcomes in CHF patients over two months.
  • Negative affectivity is a significant, stable predictor of poorer outcomes, independent of clinical factors.
  • Personality traits must be considered in the evaluation of CRT effectiveness.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Stress Prevention and Stress Management Techniques I01:26

Stress Prevention and Stress Management Techniques I

Stress prevention and management are crucial for maintaining well-being and building resilience. Techniques to manage stress include cultivating qualities like conscientiousness, a sense of personal control, and self-efficacy. Each of these traits significantly reduces stress and promotes healthier lifestyle choices and outcomes.
Conscientiousness
Conscientious individuals tend to be organized, responsible, and disciplined. They prioritize completing tasks and following structured routines,...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.